Hikal clarifies Mahad unit is operating normally

Image
Capital Market
Last Updated : Mar 12 2020 | 1:16 PM IST

The company said there has been no closure at the unit.

Hikal clarified on Wednesday (11 March 2020) that the Mahad unit, which received the closure notice from Maharashtra Pollution Control Soard (MPCB), contributed Rs 260 crore, translating to 16% of turnover of the listed entity for entire financial year 2018-19.

"There has been no closure at the said unit and the unit has been operating normally. We are working with the MPCS to resolve the matter amicably and are confident of a positive outcome," Hikal said in a release.

Hikal being a responsible care certified company stands by its commitment to long term sustainability and ethical way of doing business, it added.

On 6 March 2020, Hikal announced that it received a notice from MPCB for closure of Mahad unit based on a complaint received from the local community in Taloja. The complaint mentioned that a tanker of an authorised transporter, carrying by-product of Hikal was found near the river Kasadi in Taloja. This material was en-route for further processing to a MPCB approved manufacturer located in MIDC Dhule.

Following the order, Hikal said it was representing to MPCB for withdrawal of the closure notice and submitted all relevant documents proving that the company is not responsible for any pollution and or polluting activities in or near the river. The company also filed a writ petition in the Bombay High Court for a stay.

It, however, said that there is a possibility of some impact on the company's operations at Mahad site until this matter is resolved.

Shares of Hikal slumped 10.97% to Rs 89.25. It hit 52-week low at Rs 87.20 during intraday trade.

Hikal's consolidated net profit fell 3.5% to Rs 28.36 crore on a 3.2% slip in net sales to Rs 392.51 crore in Q3 December 2019 over Q3 December 2018.

Hikal is engaged in the manufacturing of various chemical intermediates, specialty chemicals, active pharmaceutical ingredients (APIs) and contract research activities. The firm offers pharmaceuticals and agrochemicals. Its segments include crop protection and pharmaceuticals.

Powered by Capital Market - Live News

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Mar 12 2020 | 12:32 PM IST

Next Story